Introduction
The hemostatic system involves a tight interplay between plasmatic coagulation and the activation of vascular cells, most prominently platelets. Adherence of platelets to the endothelium initiates a process of activation and aggregation that involves several surface receptors and triggers primary clot formation [1] . Plasmatic coagulation enzymes are activated by charged surfaces and by tissue factor (TF), ultimately leading to the generation of the central coagulation protease thrombin, which generates fibrin. This process is controlled by a myriad of feedback and inhibitory mechanisms [2] , and is further enhanced by the generation of microvesicles (MVs), which form an additional surface of anionic phospholipids to further support the assembly of plasmatic clotting factors [3] . Endothelial cells (ECs) not only prevent exposure of blood to procoagulatory smooth muscle cells (SMCs) and the subendothelial matrix, but are also actively involved in coagulation and the prevention thereof. Pathological activation of the hemostatic system can lead to thrombosis and thromboembolism.
Thrombosis is typically classified as arterial or venous, according to the anatomical site of occurrence. Arterial thrombosis is primarily associated with the rupture or erosion of atherosclerotic plaques, exposing prothrombotic material, in particular high local concentrations of TF [4] , whereas venous thrombosis typically occurs in low shear stress conditions in the absence of endothelial disruption [5] . Although different pathological changes underlie the development of arterial and venous thrombosis, common mechanistic pathways exist for both. For example, oxidized low-density lipoprotein (OxLDL) and its active lipid components have been primarily demonstrated to contribute to atherothrombosis either directly or by inducing inflammation, which, in turn, has been shown to promote coagulatory processes. Recent findings that the same lipid peroxidation-derived structures are also found on the surfaces of circulating MVs [6] suggest a role for oxidized lipids beyond arterial thrombosis. Therefore, understanding the mechanisms that mediate the effects of OxLDL and its active components in inflammation-driven thrombosis may provide novel insights into thromboembolic diseases. The proinflammatory properties of oxidized lipoproteins and the molecular mechanisms mediating them are reviewed extensively elsewhere [7] . In this review, we present an overview of the effects of oxidized lipoproteins on processes directly and indirectly driving coagulation and thrombosis.
Inflammation and thrombosis
The crucial contribution of inflammation to thrombosis has been a subject of investigation for many decades [8] . Indeed, atherosclerosis, which is the prerequisite for most arterial thrombotic events, is nowadays considered to be a chronic inflammatory disease of arterial blood vessels [9] . The recent conclusion of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) showing a significant benefit of the anti-interleukin (IL)-1b antibody canakinumab in the secondary prevention of atherothrombotic events has clearly demonstrated the causal involvement of inflammation in this disease process [10] . On the other hand, only a modest association between C-reactive protein (CRP) levels -as markers of inflammation -and venous thromboembolism (VTE) risk has been found, as demonstrated in a recent meta-analysis [11] . Nevertheless, increasing clinical evidence shows a close link between inflammation and venous thrombosis. For example, diseases that are associated with profound inflammation, such as inflammatory bowel disease, rheumatoid arthritis, and Behc ßet's disease, are associated with an increased risk of venous thrombotic events [12] . Thus, both arterial and venous thrombotic events are influenced by inflammatory processes.
In turn, components of both plasmatic and cellular coagulation are now recognized as promoters of inflammatory processes, and growing evidence supports an important role for platelets in inflammation in addition to their central role in thrombus formation [13] . Moreover, various members of the coagulation cascade possess biological activities that go beyond the formation of fibrin. Thrombin in particular is a central effector of cell activation, and induces inflammatory pathways via the protease-activated receptor family [14] . Thus, it is not surprising that several coagulation factors upstream of thrombin, such as TF [15] , activated factor X (FXa) [16] , FXI [17] , and FXII [18] , have been found to also propagate inflammation. Indeed, rivaroxaban, an FXa inhibitor, was recently shown to attenuate atheroscerotic plaque progression in mice, in part through inhibiting the proinflammatory activation of macrophages [19] . Furthermore, cells that are considered to be classical mediators of inflammation have been found to directly (via modulating procoagulatory and anticoagulatory pathways) and indirectly (via promoting vascular inflammation and atherosclerosis) influence thrombotic processes. This led to the development, in recent years, of the concept of immunothrombosis, which describes the role of innate immune responses, in particular by neutrophils and monocytes, in triggering prothrombotic effects [20] .
Oxidized lipoproteins and inflammation
Oxidized lipoproteins and damage-associated molecular patterns derived from them have been studied extensively in the context of inflammation and atherosclerosis in particular [21] . LDL is a complex lipoprotein containing different lipid species, including triglycerides, phospholipids, and free and esterified cholesterol. Both enzymatic and nonenzymatic mechanisms have been described that result in the oxidation of both the phospholipid and cholesterol moieties of LDL, resulting in the generation of myriads of different lipid oxidation products [22] . Oxidized cholesterol and phospholipids can in turn be hydrolyzed and release free oxidized fatty acids that decompose to malondialdehyde (MDA) and 4-hydroxy-2-nonenal, and modify LDL proteins and phospholipids. For example, when polyunsaturated fatty acids of phosphatidylcholine undergo oxidation, highly reactive decomposition products, such as MDA and 4-hydroxynonenal, are generated that form adducts with eamino groups of lysines or amino groups of other phospholipids. In addition, different species of oxidized phospholipids (OxPLs) that are derived from the truncated phospholipids are formed [23] . The contents of different lipid oxidation species are is highly dependent on the mechanisms of OxLDL generation in vitro. Nevertheless, many of the same lipid-derived structures have been described in atherosclerotic plaques, in plasma, as on the surfaces of dying cells and MVs shed by activated vascular cells (see below). Many of these are bound by both cellular and soluble receptors of innate immunity that sense and recognize certain products of lipid peroxidation such as oxidation-specific epitopes (OSEs) [21] . These include soluble pattern recognition proteins, such as CRP and certain complement factors, as well as naturally occurring IgM antibodies that mediate the clearance and removal of cellular debris and oxidized lipoproteins. Furthermore, scavenger receptors, such as CD36 and MSR-1, are critical in mediating the uptake of OxLDL, and cooperate with toll-like receptors (TLRs) to transmit proinflammatory responses in cells (Fig. 1) . Thus, various lipid peroxidation products are found in OxLDL, dying cells, and MVs, and many of them possess robust biological activities that can promote vascular pathologies.
Oxidized lipoproteins and plasmatic coagulation
The data on direct prothrombotic effects of OxLDL on plasmatic coagulation are scarce. However, it has been shown that OxLDL delays plasmatic coagulation in vitro [24] , mediated through inhibition of FVIII, FIX and FXI activity [25] . Another group, however, described increased prothrombinase activity and thrombin generation caused by OxLDL [26] . Yet another group reported that OxPLs led to increased prothrombinase activity [27] . Whether these observations are in vitro artefacts or are relevant in vivo remains to be determined. Potential inhibition of plasmatic coagulation by oxidized lipoproteins in vivo may be overshadowed by their potent activating effects on vascular cells. As discussed in depth below, the activation of various vascular cells can lead to dramatic cellular changes that can directly and indirectly modulate thrombotic processes (Fig. 2) .
Oxidized lipoproteins and platelets
Beyond their central role in thrombus formation, platelets have been recognized to play important roles in acute and chronic inflammatory pathologies that are associated with an elevated thrombotic risk [13] .
Activation of platelets upon exposure to OxLDL or OxPLs has been described [28] , and has been attributed to recognition by CD36 [29] . Genetic deletion of CD36 significantly attenuated dyslipidemia-associated increased platelet reactivity and thrombosis susceptibility in mice in vivo. Therefore, recognition of OxPLs by platelet CD36 has been proposed as a link between prothrombotic risk and dyslipidemia associated with increased oxidative stress [29] . In turn, platelets themselves can -in particular upon activation -contribute to the oxidation of lipoproteins [30] , and may thereby further propagate OxLDLinduced thromboinflammation. Platelets treated with OxLDL activate ECs and inhibit endothelial regeneration even more potently than OxLDL alone [31] . OxLDL also induces the formation of platelet-monocyte aggregates, and OxLDL-stimulated platelets have been shown to [38, 39, 47, 83] , CD36 [29, 56, 58, 59, 64, 84] , urokinase plasminogen activator recdeptor (u-PAR) [56] , toll-like receptor 4/6 (TLR4/6) [56, 59, 73] , toll-like receptor 2 (TLR2) [73] , and steroid receptor RNA activator 1 (SRA1) [58] . scavenger receptor class B type 1 (SRB1) has also been characterized as a receptor for OxLDL and oxidized phospholipids (OxPLs) [99] . ApoB, apolipoprotein B; Platelet-activating factor (PAF); Phosphatidylcholines (PCs). [Color figure can be viewed at wileyonlinelibrary.com] OxLDL AFFECTED VASCULAR CELL TYPES Platelets Activation/aggregation [28] TF [35] TF [63, 64] NF-κB activation [60] TF + MV release [64] MV release (?) [80, 81] Indirect effects via platelets EC activation [31] EC regeneration [31] Platelet-monocyte
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Effects of oxidized LDL (OxLDL) on vascular cell types in the context of thromboinflammation. OxLDL has been shown to mediate proinflammatory and procoagulatory effects on several vascular cells. EC, endothelial cell; MV, microvesicle; NET, neutrophil extracellular trap; NF-jB, nuclear factor-jB; TF, tissue factor; TFPI, tissue factor pathway inhibitor. [Color figure can be viewed at wileyonlinelibrary.com] enhance both transendothelial monocyte migration and foam cell formation in vitro [32] . Thus, platelets are potent proinflammatory and prothrombotic mediators of the effects of OxLDL.
OxLDL and ECs
Resting ECs are powerful inhibitors of coagulation by displaying tissue factor pathway inhibitor (TFPI), heparan sulfate proteoglycans and thrombomodulin on their surfaces. Furthermore, ECs are important modulators of fibrinolysis by expressing tissue-type plasminogen activator (t-PA) [33] . Proinflammatory activation of ECs leads to a shift towards a prothrombotic state by downregulation of those factors, as well as by the induction of several procoagulant pathways, including the release of stored von Willebrand factor and the expression of adhesion molecules and TF [34] . Furthermore, activated ECs express adhesion molecules on their surfaces, thus recruiting leukocytes and platelets, which can initiate further thromboinflammatory pathways.
Studies in the early 1990s demonstrated that incubation of ECs with OxLDL results in changes in the expression profile of proteins involved in coagulatory processes, including TF expression [35] . Although OxPLs and OxLDL have been demonstrated to induce TF expression on ECs [36] , the functional role that this effect has in thrombosis is unclear, as EC-derived TF (in contrast to TF expressed by SMCs and hematopoietic cells) is not considered to play a major role in pathological coagulation [37] . Nevertheless, TF expressed by ECs could contribute indirectly by enhancing inflammatory processes. Lectin-like oxidized LDL receptor-1 (LOX-1) has been identified as a receptor for OxLDL [38] . Interestingly, EC-specific LOX-1 transgenic mice showed attenuated carotid artery thrombosis, accompanied by activation of the Oct-1-SIRT1 pathway in the vasculature. However, direct injection of OxLDL or a Western-type diet (which presumably increases OxLDL levels) led to activation of the Ras-Raf-1-extracellular signal-related kinase 1/2 pathway in the vasculature and increased thrombosis in the transgenic animals [39] . Thus, OxLDL mediates prothrombotic effects via ECs in a LOX-1-dependent manner. Further insights into the proinflammatory and prothrombotic functions of OxLDL came from detailed characterization of its biologically active components, most prominently OxPLs, that were isolated from minimally oxidized LDL [40] . Interestingly, OxPLs induce the recruitment and adhesion of monocytes but not neutrophils to ECs in vitro and in vivo [23] . This is in part mediated by OxPLs-dependent expression of b 1 integrins [41] and P-selectin [42] on the surfaces of ECs. Moreover, a number of chemokines and cytokines, such as IL-8, monocyte chemoattractant protein-1 (MCP-1), and vascular endothelial growth factor A, have been shown to be expressed upon stimulation of ECs with OxPLs [23] , which may further promote the migration of leukocytes and vascular inflammation. Moreover, OxPLs have also been found to bind and dramatically reduce the activity of TFPI [43] and to downregulate thrombomodulin expression in ECs [44] . Therefore, OxPLs are robust inducers of a proinflammatory and procoagulant EC phenotype. Additionally, oxidized cholesteryl esters, which are known to be present in OxLDL, induce adhesion of monocytes to ECs, and thereby promote atherogenesis and directly contribute to procoagulatory processes [45] .
Apart from the direct effects that OxLDL and its active lipid components exert on ECs in causing them to switch from an anticoagulatory to a procoagulatory phenotype, they may also influence the clinical complications of plaque development by promoting plaque destabilization, rupture, and erosion, ultimately leading to atherothrombotic events. Indeed, OxPLs have been shown to induce, in human umbilical vein endothelial cells, the expression of ADAMTS-1 metalloproteinase, which can degrade plaque matrix components and therefore promote atherosclerotic plaque instability [46] . Moreover, OxLDL [47] and OxPLs [46] have been reported to promote angiogenic responses in vitro and in vivo, and these, in turn, also contribute to plaque instability and atherothrombotic complications.
Altogether, these data identify potent activities of OxLDL and its active lipid components in promoting vascular inflammation and altering ECs to be potentially more procoagulant, in addition to recruiting other cells that support thromboinflammatory pathways.
Oxidized lipoproteins and vascular SMCs (VSMCs)
VSMCs are not exposed to blood flow under physiological conditions, but have an essential role in hemostasis by exposing TF upon vessel injury. They promote atherosclerotic plaque stability by producing and excreting extracellular matrix proteins [48] . Inflammatory stimuli lead to VSMC activation and the secretion of matrix metalloproteinases. Furthermore, similarly to macrophages, SMCs can transform into foam cells [49] .
OxLDL has been shown to induce SMC-derived foam cells [50] , and has other biological activities, including chemotactic [51] and proliferative effects [52] on VSMCs. OxPLs have also been found to induce a phenotypic switch and the expression of proinflammatory genes, such as those encoding MCP-1, monocyte chemoattractant protein-3, and cytolysin, in VSMCs [53] . Interestingly, native LDL was found to induce increased inactive TF expression in SMCs [54] , whereas incubation with OxLDL leads to increased expression of its active form [55] . This suggests that oxidative modification of LDL is a prerequisite for induction of functional TF expression as opposed to increased inactive TF expression. More recently, a study revealed that OxLDL triggers the association of urokinase plasminogen activator receptor (u-PAR) with CD36 and TLR4, forming a cluster of pattern recognition receptors (PRRs) that drive phenotypic changes and granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor secretion by VSMCs [56] . The authors proposed that this might, in turn, affect macrophage activation in atherosclerotic lesions. Whether these findings also affect the plasminogen activation system, which u-PAR drives by binding urokinase, remains to be elucidated.
Therefore, oxidized lipoproteins may also contribute to atherothrombosis by affecting VSMCs, which are known to play an important role in plaque development and stability -critical determinants of the atherothrombotic risk.
Oxidized lipoproteins and leukocytes
Monocyte-derived macrophages are considered to be hallmark cells of atherosclerotic lesions, and thereby major contributors to arterial thrombosis, as reviewed in detail by Moore and Tabas [57] . Following activation by OxLDL, ECs express chemokines and adhesion molecules that mediate the recruitment of monocytes to the artery wall, where they differentiate into macrophages that further promote the oxidation of LDL by generating reactive oxygen species (ROS) as well as by enzymatic processes. OxLDL is taken up by macrophages via mechanisms that involve scavenger receptors such as CD36 and SR-A [58] . At the same time, OxLDL and OxPLs engage a CD36-TLR4-TLR6 heterotrimer to induce the expression of proinflammatory, mostly nuclear factor-jB-dependent, genes, including chemokines, cytokines, and NACHT, LRR and PYD domain-containing protein 3 (NLRP3) [59] . Similar proinflammatory properties have been shown for MDA adducts, although different signaling mechanisms seem to be involved [60] . Following uptake of OxLDL, intracellular cholesterol crystals are formed, and these act as ligands for the NLRP3 inflammasome, leading to its activation and the production of IL-1b and IL-18 [61] . In analogy to what has been found for both VSMCs and ECs, OxLDL has been demonstrated to induce the expression of matrix metalloproteinases in macrophages [62] . OxLDL has also been shown to both induce TF expression on its own and enhance the lipopolysaccharide-induced expression of TF in monocytes [63] . This is supported by the observation that hypercholesterolemic animals have elevated levels of circulating OxLDL, increased activation of coagulation, and higher TF expression on leukocytes [64] . The authors further demonstrated that OxLDL induces TF expression in THP-1 monocytes in a TLR4-dependent manner in vitro, and that the hypercholesterolemia-induced procoagulatory phenotype was dramatically reduced in TLR4
-/-and TLR6 -/-mice. Thus, OxLDL and its components propagate thromboinflammatory processes via monocytes/ macrophages in atherosclerosis. In contrast, so far, only a few studies have investigated the role of monocytes in venous thrombosis. Monocytes are present in venous thrombi, where they support thrombus formation by expressing TF upon activation [65] . On the other hand, they are critical mediators of venous thrombus resolution, particularly through the expression of urokinase plasminogen activator and t-PA [66, 67] .
In recent years, the role of neutrophils in cardiovascular disease (CVD) has gained increasing attention. Although they are not as prominently present in atherosclerotic lesions as monocyte/macrophages, they have been shown to contribute to lesion development [68] . Because of their oxidative burst capacity, neutrophils themselves may also mediate the oxidation of LDL [69] . OxLDL has been shown to induce superoxide generation in neutrophils [70] , which propagates further lipid peroxidation. Furthermore, OxLDL decreases neutrophil membrane fluidity while upregulating expression of the CD11b-CD18 adhesion receptor complex, which is a core inflammatory effector mediating adhesion and migration of leukocytes [71] .
In addition to their role in vascular inflammation, neutrophils have gained much attention in thrombosis research in recent years with the discovery of neutrophil extracellular traps (NETs) and the subsequent finding that NETs promote coagulation and thrombosis [72] . Recently, it has been shown that OxLDL, and two of its components, lysophosphatidylcholine and oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine in particular, are potent inducers of NETosis [73] , and can therefore promote vascular inflammation and thrombosis via NET formation. Thereby, OxLDL exerts multiple effects on neutrophils that may contribute to thrombosis by promoting further amplification of lipoprotein oxidation, activation of vascular cells, and the release of NETs.
Although very little is known about the role of lymphocytes in thromboinflammation, they may mediate indirect effects. OxLDL-specific T and B cells have been described, and their role in atherosclerosis is discussed extensively elsewhere [74] . These cellular responses may also modulate processes of thrombosis more directly, as effector memory T cells were recently demonstrated to affect venous thrombus resolution by recruiting monocytes and neutrophils into post-thrombotic vein walls [75] . Furthermore, certain T-cell clones derived from atherosclerotic lesions have been shown to recognize OxLDL [76] . Whether OxLDL-induced T-cell activation plays a significant role in directly affecting thrombotic processes remains to be elucidated. B cells, on the other hand, may modulate thrombosis via the secretion of antibodies. Natural IgM antibodies with specificity for oxidation-specific epitopes protect against OxLDL-induced inflammation and atherosclerosis [77] . A number of epidemiological studies have also demonstrated an inverse association between OxLDL-specific IgM antibody titers and cardiovascular events. This protective effect of B cells is mediated by the subset of B1a cells, which produce natural IgM antibodies, a large percentage of which are reactive to OxLDL [78] . Furthermore, a recent study found an inverse association between IgM antibodies reactive to OxLDL and phosphatidylcholine (PC) and recurrent venous thrombosis in patients with unprovoked VTE [79] . This finding suggests a potential value of certain IgM antibodies in predicting and lowering the venous thrombotic risk.
MVs and oxidized lipoproteins
MVs constitute a subclass of extracellular vesicles (100-1000 nm in diameter), and are released by blebbing of the cytoplasmic membranes of resting and activated cells. Circulating MVs can originate from different parental cells, including platelets, red blood cells, leukocytes, and ECs [3] . Because of the exposure of phosphatidylserine and, in some cases, TF on their surfaces, MVs are potent inducers of coagulation [3] . Similarly to OxLDL, MVs have been reported to accumulate in atherosclerotic plaques and proposed to promote their progression. Moreover, cell activation by different stimuli (including OxLDL) has been shown to induce the release of procoagulatory and proinflammatory MVs [3] . Thus, similarly to OxLDL, MVs can indirectly elevate the thrombotic risk by inducing diverse inflammatory responses, but also directly activate coagulation.
Activation of platelets upon exposure to OxLDL or OxPLs has been described [28] . However, studies investigating whether stimulation with OxLDL leads to platelet MV release in vitro are contradictory [80, 81] . In either case, the effects of OxLDL on the release of MVs by platelets in vivo remain to be elucidated. Stimulation of ECs with OxLDL has also been found to trigger the release of MVs, which, in turn, induce the expression of ICAM-1 and promote monocyte adhesion to ECs [82] . However, a direct procoagulatory role for OxLDL-induced ECderived MVs still needs to be established.
OxLDL has also been demonstrated to induce the release of of highly procoagulant TF-expressing MVs by monocytes in vitro [64] . The authors also found elevated numbers of circulating TF-expressing MVs in animal models of hypercholesterolemia as well as in patients with familial hypercholesterolemia [64] .
Recently, we showed that a subset of in vitro-generated and circulating MVs of different cellular origin is characterized by the presence of the same OSEs that are found in OxLDL [6] . These products can be either inherited from parental cells or newly formed upon enzymatic and non-enzymatic modification after MV release analogous to the modification of LDL. Consistent with this, cholesterol loading of macrophages has been shown to promote the release of MVs that carry MDA epitopes [83] . OSEs present on MVs may also contribute to prothrombotic and proinflammatory processes by interacting with the same PRRs and inducing similar functional effects as active OxLDL components. For example, MVs released by cholesterol-loaded macrophages were found to induce endothelial activation and leukocyte adhesion to postcapillary venules in mice in vivo [83] . This effect was significantly reduced in LOX-1-deficient mice or upon treatment with anti-LOX-1 antibodies, suggesting that these effects are mediated by OSEs [83] . Moreover, similarly to OxLDL, a critical role for CD36 on platelets in enhancing ADP-dependent platelet activation and aggregation by EC-derived MVs has been demonstrated [84] . These effects are also probably dependent on the exposure of OSEs on EC-derived MVs. On the other hand, the same components of innate immunity that are known to protect against OxLDL-mediated effects may also reduce thromboinflammatory responses induced by MVs. Notably, we have shown that 50% of circulating MVs are recognized by natural IgM that also bind OxLDL [6] . The ability of MDA-positive MVs to induce IL-8 secretion in monocytes was significantly reduced in the presence of a monoclonal IgM antibody with specificity for MDA adducts, which are also present on OxLDL [6] . A similar effect has also been described for PC-specific IgM antibodies, which neutralized the capacity of apoptotic blebs to mediate activation of and subsequent monocyte adhesion to ECs [45] . Whether OxLDL-specific IgM antibodies could also directly inhibit the procoagulatory effects of OSE-carrying MVs remains to be demonstrated.
Thus, OxLDL induces the cellular release of MVs, which can directly promote coagulation by the exposure of active TF, and indirectly promote it by propagating inflammatory responses. The latter may be mediated by the presence of the same OSEs that are present on OxLDL and recognized by the same PRRs. Although MVs have been shown to inherit the surface molecules of their parental cells and presumably PRRs such as CD36, possible interactions of OxLDL with MVs and the functional consequences thereof are unknown. One may speculate that recognition of OxLDL by PRRs present on MVs may compete with cellular recognition of OxLDL and therefore serve as a mechanism limiting overt thromboinflammation. The evaluation of OSE-carrying MVs may have prognostic value in CVD and associated thrombotic events, as has been shown for OxLDL.
Oxidized lipoproteins as a risk factor for thrombosis in clinical studies
Many studies have presented clinical evidence for a relationship between plasma OxLDL levels and arterial CVD. Measurements of OxLDL were shown to be highly sensitive and specific in discriminating stable and unstable coronary artery disease (CAD) [85] . Furthermore, the amount of OxPLs bound to apoB-100 and, more specifically, Lp(a) lipoprotein levels have been identified as strong predictors of the presence and extent of CAD [86] . Thus, OxPLs have been suggested to constitute a predictive biomarker of arterial cardiovascular events. A major limitation of these studies is the heterogeneity and the lack of robustness of the OxLDL measurements employed. Only reproducible assays that determine the levels of specific components of OxLDL, such as OxPLs, independently of total LDL levels will provide reliable insights. Nevertheless, OxLDL (or its components) may be a useful biomarker in the assessment and prediction of atherothrombotic risk.
In contrast to the many studies investigating OxLDL in arterial thrombosis, only a single study has investigated the relationship between OxLDL and venous thrombosis. Slightly elevated levels of OxLDL were found in a small cohort of patients suffering from antiphospholipid syndrome (APS) who had developed venous thrombosis [87] . However, these findings might be confounded by the presence of autoantibodies recognizing OxLDL-b 2 GPI complexes in APS patients. Clearly, there is a need for more studies investigating OxLDL levels with reliable assays in different and larger cohorts at risk for venous thrombosis to determine whether it can serve as a biomarker for VTE. Considering the similarities between OxLDL and MVs, quantifying the levels of the latter, in particular the subset carrying OSE, may also provide important insights.
Targeting lipoproteins as a preventive measure in thrombosis
The classical anticoagulatory drugs used to prevent arterial and venous thrombosis also increase the risk of bleeding complications. Therefore, targeting other risk factors of thrombosis might provide an alternative approach to reduce thrombotic risk in certain situations.
Statins are widely used to lower LDL cholesterol in the primary and secondary prevention of CVD caused by atherosclerosis [88] . Additionally, statins have been found to lower the risk of venous thrombosis, as first reported in a large-scale retrospective study by Ray et al. [89] , an effect that was not observed for non-statin lipid-lowering agents. More recently, Glynn et al. confirmed the protective effects of statins in venous thrombosis in a prospective randomized trial [90] . In this subanalysis of the JUPITER trial, apparently healthy individuals with normal lipid profiles treated with rosuvastatin developed significantly fewer VTEs. However, a population-based cohort study found no association between overall lipid levels and VTE [91] . Additional benefits of statins that are independent of LDL cholesterol lowering have been described and termed 'pleiotropic effects'. Several pleiotropic effects might directly and indirectly affect thrombotic processes, such as altering the expression of endothelial nitric oxide synthase, atherosclerotic plaque stabilization, lowering platelet reactivity, and the production of proinflammatory cytokines and ROS [92] . Interestingly, a study investigating the levels of OxLDL and the severity of CAD found that patients undergoing statin treatment had significantly lower levels of OxLDL than untreated patients [93] . Furthermore, a prospective study investigating the effect of atorvastatin treatment on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome found a dose-response relationship for atorvastatin in its capacity to lower OxLDL levels [94] . Another group comparing atorvastatin treatment with atorvastatin/ezetimibe treatment showed that the addition of ezetimibe, while lowering total LDL levels, did not affect OxLDL levels [95] . Notably, Owens et al. demonstrated that simvastatin treatment reduced the prothrombotic phenotype in experimental animal models of hypercholesterolemia [64] . Interestingly, simvastatin treatment resulted in lower OxLDL levels without changing total LDL levels.
Thus, total LDL lowering in itself, although of great benefit in the prevention of arterial thrombosis, does not seem to affect the risk of developing venous thrombosis. However, in addition to their capacity to affect total LDL levels, statins also lower VTE risk, which has not been observed with non-statin lipid-lowering drugs. The positive effect of statin treatment on VTE risk might be related to their capacity to reduce oxidative stress, and possibly to lower OxLDL. The potential changes in OxLDL levels caused by statin treatment might be explained by their general anti-inflammatory effects. However, CRP and OxLDL levels have shown no correlation with each other in a majority of studies [96] , suggesting other mechanisms. Moreover, these data should be interpreted with caution, because OxLDL measurements are not standardized, and are variable in their quality.
Another -more direct -approach to consider in modulating thromboinflammation induced by OxLDL could be based on specific antibodies. Anti-OxLDL IgM antibodies protect against atherosclerosis, and several studies have shown a correlation between low levels of anti-OxLDL IgM antibodies and an increased risk of CAD [21] . Thus, the protective capacity of IgM antibodies with specificity for oxidation-specific epitopes could be exploited for therapeutic purposes. Indeed, beyond their neutralizing activity on OxLDL, these antibodies also target MVs, and therefore may have indications beyond atherosclerotic CVD. Interestingly, epidemiological data suggest a connection between low levels of total IgM antibodies and long-term venous thrombotic risk after splenectomy [97] . Additionally, an inverse correlation between OxLDL-specific IgM levels and recurrence of venous thrombosis has recently been demonstrated [79] , as discussed above. Strategies to boost OxLDL-specific antibody production that are being investigated may provide potential tools with which to prevent inflammation and thrombosis. These could include vaccination approaches, passive infusions with purified IgM antibodies, or the targeting of negative regulators of IgM production on B cells. In murine models, these intervention strategies have demonstrated profound effects on atherosclerotic lesion formation and inflammation in general [60, 77, 98] . Translating these approaches into use in humans will be a major challenge in the future.
Conclusion
Various ligands of microbial and sterile origin have been shown to promote thrombosis either directly or by driving inflammatory responses. OxLDL represents a prominent driver of vascular inflammation and atherothrombotic events. The underlying mechanisms by which OxLDL promotes atherosclerosis initiation and progression and subsequently arterial thrombosis (e.g. foam cell formation and plaque matrix degradation) are well recognized. Although these effects are not relevant in the pathophysiology of venous thrombosis, OxLDL and its biologically active components have nevertheless been shown to directly and indirectly promote coagulation and thrombosis. Notably, many of the same biologically active components that are found on OxLDL are present on a subset of circulating MVs, which are considered to be critical mediators of arterial and venous thrombosis. Investigating the contribution of oxidized lipoproteins in the context of these findings will provide novel insights and identify new pathways of thromboinflammation. Understanding the function and targeting the generation and activities of active components of OxLDL and OSE-carrying MVs may provide novel therapeutic approaches to prevent thromboinflammatory diseases.
